{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:25:17Z","timestamp":1793291117364,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.phrs.2021.105701","type":"journal-article","created":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T12:22:56Z","timestamp":1622550176000},"page":"105701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer"],"prefix":"10.1016","volume":"170","author":[{"given":"Xueting","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongwei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Molina-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Chaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.phrs.2021.105701_bib1","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/s41388-019-1104-z","article-title":"Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation","volume":"39","author":"Jin","year":"2020","journal-title":"Oncogene"},{"issue":"18","key":"10.1016\/j.phrs.2021.105701_bib2","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2021.105701_bib3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"5687","key":"10.1016\/j.phrs.2021.105701_bib4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Sordella","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.phrs.2021.105701_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","article-title":"Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells","volume":"26","author":"Lee","year":"2014","journal-title":"Cancer Cell"},{"issue":"29","key":"10.1016\/j.phrs.2021.105701_bib6","doi-asserted-by":"crossref","first-page":"47305","DOI":"10.18632\/oncotarget.17625","article-title":"Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)","volume":"8","author":"Codony-Servat","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.phrs.2021.105701_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx014","article-title":"Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) pathway in EGFR-mutant NSCLC","volume":"109","author":"Chaib","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"issue":"8","key":"10.1016\/j.phrs.2021.105701_bib8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2021.105701_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ebiom.2018.02.001","article-title":"Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive non-smallcell lung cancer associated with poor prognosis","volume":"29","author":"Karachaliou","year":"2018","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.phrs.2021.105701_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s43018-020-0048-0","article-title":"EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer","volume":"1","author":"Gong","year":"2020","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2021.105701_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.celrep.2015.03.012","article-title":"NF-kappaB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer","volume":"11","author":"Blakely","year":"2015","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.phrs.2021.105701_bib12","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1172\/JCI96148","article-title":"TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer","volume":"128","author":"Gong","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.phrs.2021.105701_bib13","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2337\/diabetes.53.4.1052","article-title":"Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?","volume":"53","author":"Brunmair","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2021.105701_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.2553","article-title":"Effect of Metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 Randomized Clinical Trial","volume":"5","author":"Arrieta","year":"2019","journal-title":"JAMA Oncol."},{"issue":"7751","key":"10.1016\/j.phrs.2021.105701_bib15","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41586-019-1005-x","article-title":"Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism","volume":"568","author":"Lee","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105701_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13578-018-0257-8","article-title":"Essential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis","volume":"8","author":"Kalainayakan","year":"2018","journal-title":"Cell Biosci."},{"issue":"2","key":"10.1016\/j.phrs.2021.105701_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cell.2019.06.005","article-title":"BACH1 stabilization by antioxidants stimulates lung cancer metastasis","volume":"178","author":"Wiel","year":"2019","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.phrs.2021.105701_bib18","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1158\/0008-5472.CAN-18-2156","article-title":"Elevated heme synthesis and uptake underpin intensified oxidative metabolism and tumorigenic functions in non-small cell lung cancer cells","volume":"79","author":"Sohoni","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2021.105701_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10111","article-title":"Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2021.105701_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1017\/S1462399409001239","article-title":"Anticancer activities of artemisinin and its bioactive derivatives","volume":"11","author":"Firestone","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.phrs.2021.105701_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/247597","article-title":"Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug","volume":"2012","author":"Crespo-Ortiz","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105701_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00450-6","article-title":"Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer","volume":"8","author":"Jacobsen","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.phrs.2021.105701_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09734-5","article-title":"AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy","volume":"10","author":"Bertran-Alamillo","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.phrs.2021.105701_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2021.105701_bib25","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/j.cellsig.2014.07.001","article-title":"Potent proapoptotic actions of dihydroartemisinin in gemcitabine-resistant A549 cells","volume":"26","author":"Zhao","year":"2014","journal-title":"Cell Signal."},{"issue":"3","key":"10.1016\/j.phrs.2021.105701_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1349-7006.2008.01066.x","article-title":"Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung","volume":"100","author":"Ikeda","year":"2009","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.phrs.2021.105701_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(17)30480-0","article-title":"Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study","volume":"6","author":"Lin","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"14","key":"10.1016\/j.phrs.2021.105701_bib28","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.1074\/jbc.M114.631580","article-title":"Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells","volume":"290","author":"Okon","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.phrs.2021.105701_bib29","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1038\/sj.emboj.7600248","article-title":"Heme regulates gene expression by triggering Crm1-dependent nuclear export of Bach1","volume":"23","author":"Suzuki","year":"2004","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.phrs.2021.105701_bib30","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cell.2019.06.003","article-title":"Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1","volume":"178","author":"Lignitto","year":"2019","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.phrs.2021.105701_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134777","article-title":"NRF2, a transcription factor for stress response and beyond","volume":"21","author":"He","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.phrs.2021.105701_bib32","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1089\/ars.2017.7176","article-title":"The roles of NRF2 in modulating cellular iron homeostasis","volume":"29","author":"Kerins","year":"2018","journal-title":"Antioxid. Redox Signal."},{"issue":"22","key":"10.1016\/j.phrs.2021.105701_bib33","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.10.80","article-title":"Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma","volume":"7","author":"Chaib","year":"2019","journal-title":"Ann. Transl. Med."},{"issue":"10","key":"10.1016\/j.phrs.2021.105701_bib34","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1509150","article-title":"Dihydroartemisinin\u2013Piperaquine for the prevention of malaria in pregnancy","volume":"374","author":"Kakuru","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821002851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821002851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:27:17Z","timestamp":1760912837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821002851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":34,"alternative-id":["S1043661821002851"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105701","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105701"}}